NCT06346067 2026-02-27A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)Erasca, Inc.Phase 3 Active not recruiting78 enrolled
NCT00600496 2025-11-13A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)AstraZenecaPhase 1 Active not recruiting140 enrolled